
Study compares Zepbound and Wegovy for weight loss in direct comparison
Fox News
A new study compares the effectiveness of weight-loss drugs tirzepatide and semaglutide, finding tirzepatide leads to greater weight loss and waist reduction.
Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. "Doctors, insurance companies and patients are always asking, ‘Which drug is more effective?’" "Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." Melissa Rudy is senior health editor and a member of the lifestyle team at Fox News Digital. Story tips can be sent to melissa.rudy@fox.com.
The randomized, controlled trial — called SURMOUNT-5 — included 751 people throughout the U.S. and Puerto Rico who had obesity but not type 2 diabetes.













